Study summary · research use only
A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this equine (horse) plasma method-development study, the authors describe an LC-MS/MS confirmation method for CJC-1295, a growth-hormone-releasing peptide that covalently binds plasma proteins such as serum albumin via a C-terminal maleimido group, extending its half-life and allowing it to stimulate growth hormone production for more than six days in humans after a single dose. Because conjugated CJC-1295 is difficult to detect by mass spectrometry due to low abundance, high molecular weight, and variable protein conjugation, the authors used immuno-affinity capture and tryptic digestion followed by LC-MS/MS, building on a previously described immuno-PCR screening method. Using this approach, CJC-1295 was identified in equine plasma down to concentrations as low as 180 pg/mL in 1 mL of sample.
Abstract
CJC-1295 is a peptide-based drug that stimulates the production of growth hormone (GH) from the pituitary gland. It incorporates a functional maleimido group at the C-terminus that allows it to covalently bind plasma proteins such as serum albumin. These CJC-1295-protein conjugates have a much greater half-life compared to the unconjugated peptide and are capable of stimulating GH production for more than six days in humans after a single administration. Conjugated CJC-1295 is difficult to detect in blood by mass spectrometry due to its low abundance, high molecular weight, and conjugation to a range of different protein substrates. Previously we described a screening procedure for the detection of CJC-1295 in equine plasma using an immuno-PCR assay. Here we demonstrate the confirmation of CJC-1295 in equine plasma by LC-MS/MS after immuno-affinity capture and tryptic digestion. Using this method, CJC-1295 was identified down to concentrations as low as 180 pg/mL in 1 mL of equine plasma.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.